Desmoid tumours in patients with familial adenomatous polyposis and desmoid region adenomatous polyposis coli mutations

被引:39
作者
Speake, D.
Evans, D. G.
Lalloo, F.
Scott, N. A.
Hill, J.
机构
[1] Manchester Royal Infirm, Dept Surg, Colorectal Unit, Manchester M13 9WL, Lancs, England
[2] Hope Hosp, Dept Colorectal Surg, Manchester, Lancs, England
[3] St Marys Hosp, Dept Clin Genet, Manchester M13 0JH, Lancs, England
关键词
MOLECULAR-GENETIC TESTS; HIGH-DOSE TAMOXIFEN; SURGICAL-MANAGEMENT; AGGRESSIVE FIBROMATOSIS; 1ST-LINE TREATMENT; COLORECTAL-CANCER; APC; SULINDAC;
D O I
10.1002/bjs.5633
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The aim of this study was to determine the proportion of patients with familial adenomatous polyposis (FA-P) who had mutations in the desmoid region of the adenomatous polyposis coli (APC) gene that phenotypically expresses desmoid disease, and to determine the role for surgery in these patients. Methods: Data from the North West Region FAP database and case notes were analysed retrospectively. Results: Of 3 63 patients with FAP, 47 from ten families had APC mutations in the desmoid region 3 ' to codon 1399. Of 22 patients undergoing surgery, 16 developed desmoids, and of these 12 had mesenteric desmoid disease. Complications from mesenteric desmoids were death (two patients), enterectomy (three), local resection (three), fistula (one), cholangitis and local resection (one), bowel obstruction (one) and bowel and ureteric obstruction (one). Preoperative polyp burden ranged from 0 to 100 in eight patients (median age 24.5 (range 16-39) years) and more than 100 in seven (median age 39 (range 31-64) years). One patient had no record of polyp burden. Conclusion: In individuals with 3 ' APC mutations, abdominal surgery is associated with a 65 per cent risk of developing mesenteric desmoids. An alternative strategy might be to attempt to manage the polyps endoscopically.
引用
收藏
页码:1009 / 1013
页数:5
相关论文
共 25 条
  • [1] MORTALITY IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS
    ARVANITIS, ML
    JAGELMAN, DG
    FAZIO, VW
    LAVERY, IC
    MCGANNON, E
    [J]. DISEASES OF THE COLON & RECTUM, 1990, 33 (08) : 639 - 642
  • [2] Bertario L, 2001, INT J CANCER, V95, P102, DOI 10.1002/1097-0215(20010320)95:2<102::AID-IJC1018>3.0.CO
  • [3] 2-8
  • [4] FAMILIAL ADENOMATOUS POLYPOSIS - MUTATION AT CODON-1309 AND EARLY-ONSET OF COLON-CANCER
    CASPARI, R
    FRIEDL, W
    MANDL, M
    MOSLEIN, G
    KADMON, M
    KNAPP, M
    JACOBASCH, KH
    ECKER, KW
    KREISSLERHAAG, D
    TIMMERMANS, G
    PROPPING, P
    [J]. LANCET, 1994, 343 (8898) : 629 - 632
  • [5] Desmoid tumours complicating familial adenomatous polyposis
    Clark, SK
    Neale, KF
    Landgrebe, JC
    Phillips, RKS
    [J]. BRITISH JOURNAL OF SURGERY, 1999, 86 (09) : 1185 - 1189
  • [6] DAVIES DR, 1995, AM J HUM GENET, V57, P1151
  • [7] Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome
    Dunlop, MG
    [J]. GUT, 2002, 51 : V21 - V27
  • [8] Molecular genetic tests in surgical management of familial adenomatous polyposis
    Evans, DGR
    Hill, J
    Dudding, T
    Burn, J
    Maher, ER
    [J]. LANCET, 1997, 350 (9093) : 1777 - 1777
  • [9] Can APC:: mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis?: Experience from 680 FAP families
    Friedl, W
    Caspari, R
    Uhlhaas, S
    Lamberti, C
    Jungck, M
    Kadmon, M
    Wolf, M
    Fahnenstich, J
    Gebert, J
    Möslein, G
    Mangold, E
    Propping, P
    [J]. GUT, 2001, 48 (04) : 515 - 521
  • [10] High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors
    Hansmann, A
    Adolph, C
    Vogel, T
    Unger, A
    Moeslein, G
    [J]. CANCER, 2004, 100 (03) : 612 - 620